What is a radiopharmaceutical?
A radiopharmaceutical is a compound consisting of a radioactive isotope attached to a biologically active molecule, designed to target specific tissues or physiological processes within the body.
A radiopharmaceutical combines a radionuclide with a biologically active molecule to enable targeted functional imaging in nuclear medicine.
The radioactive component (the radionuclide) allows detection using nuclear medicine imaging, while the pharmaceutical component determines the biological distribution. Together, they enable functional imaging of organs, metabolism, perfusion, or receptor expression.
Radiopharmaceuticals are central to both SPECT and PET imaging.
Understanding the physics
A radiopharmaceutical has two essential parts:
The radionuclide – provides the detectable radiation signal (gamma emission for SPECT, positron emission for PET).
The carrier molecule – determines where in the body the compound travels and accumulates.
For example, in FDG PET:
Fluorine-18 is the radionuclide.
Fluorodeoxyglucose is the glucose analogue that participates in cellular metabolism.
The biological behaviour of the compound is determined almost entirely by the carrier molecule, not the radiation.
The radionuclide must have physical properties compatible with imaging:
Suitable half-life
Appropriate radiation energy
Minimal particulate emission
The biological half-life of the pharmaceutical determines how long it remains in target tissues. The physical half-life of the radionuclide determines how long it emits detectable radiation. These combine to determine imaging timing and radiation dose.
The ideal radiopharmaceutical:
Targets the organ or receptor of interest
Has minimal non-target uptake
Is stable in vivo
Clears from background tissues appropriately
Matches physical half-life to biological kinetics
Radiopharmaceutical design integrates nuclear physics, chemistry, and physiology.
Where this matters clinically
Different radiopharmaceuticals are used to image different physiological processes, such as bone turnover, myocardial perfusion, glucose metabolism, or receptor expression.
Understanding the structure of radiopharmaceuticals explains why biodistribution patterns differ between tracers and why image timing is important.